Gemopatrilat
Gemopatrilat[edit | edit source]
Gemopatrilat is a pharmacological agent that functions as a vasopeptidase inhibitor. It is primarily studied for its potential use in the treatment of hypertension and congestive heart failure. Gemopatrilat is a dual inhibitor, targeting both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP), which are enzymes involved in the regulation of blood pressure.
Mechanism of Action[edit | edit source]
Gemopatrilat works by inhibiting the activity of two key enzymes:
- Angiotensin-Converting Enzyme (ACE): This enzyme is responsible for the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that increases blood pressure. By inhibiting ACE, gemopatrilat reduces the production of angiotensin II, leading to vasodilation and decreased blood pressure.
- Neutral Endopeptidase (NEP): NEP breaks down natriuretic peptides, which are hormones that promote vasodilation and natriuresis (excretion of sodium in urine). Inhibition of NEP by gemopatrilat results in increased levels of natriuretic peptides, further contributing to the reduction of blood pressure.
Clinical Applications[edit | edit source]
Gemopatrilat has been investigated for its potential benefits in treating conditions such as:
- Hypertension: By lowering blood pressure through dual inhibition of ACE and NEP, gemopatrilat may offer advantages over traditional ACE inhibitors.
- Congestive Heart Failure: The combined effects of vasodilation and natriuresis can help alleviate symptoms of heart failure by reducing the workload on the heart and promoting fluid excretion.
Development and Research[edit | edit source]
Research into gemopatrilat has focused on its efficacy and safety profile compared to other antihypertensive agents. Studies have explored its impact on blood pressure control, cardiovascular outcomes, and potential side effects. However, concerns about adverse effects, such as angioedema, have influenced its development and clinical use.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
